31-GEP Prognostic Assay for Melanoma

Conclusions

• The current AJCC staging system may have significant limitations in accurately predicting outcomes for melanoma patients, leading to discrepancies in risk assessment.
• A substantial number of melanoma deaths occur in patients diagnosed at early stages, emphasizing the need for improved risk stratification.
• The 31-GEP assay provides a molecular approach that allows for more personalized risk assessments of recurrence and metastasis compared to traditional staging methods.
• Results from the 31-GEP assay classify melanoma patients into different risk categories, with Class 1 patients having significantly better 5-year disease-free survival compared to Class 2 patients.
• Patients classified as Class 2B exhibit markedly higher metastatic risks and worse outcomes, suggesting their identification is crucial for management decisions.
• Evidence supports that the 31-GEP test can improve the prediction of sentinel lymph node positivity, ultimately guiding the clinical decision for SLNB procedures.
• The use of the 31-GEP assay has demonstrated clinical utility by reducing unnecessary sentinel lymph node biopsies in low-risk patient populations.
• Outcomes from 31-GEP testing suggest potential survival benefits and improved prognostication when integrated with traditional clinicopathologic factors.
• Long-term validation studies indicate that the 31-GEP assay can consistently stratify patients and potentially improve management strategies.
• There is a growing body of literature supporting the use of GEP testing in clinical practice for melanoma, reinforcing its role in personalized cancer care.